✨ Free AI Report
Zura Bio Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Zura Bio Limited
Company Research

Zura Bio Limited: Business Overview, Financials & Competitive Analysis

Zura Bio Limited scores 7/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage immunology biotech with dual near-term catalysts and sufficient funding through key trial readouts in 2026-2027. The company highlighted two potentially transformative readouts expected over the next 18 months with tibulizumab as a lead bispecific program. With $139.0 million in cash and cash equivalents as of September 30, 2025.

What is Zura Bio Limited's industry? Zura Bio Limited (zurabio.com) operates in Clinical-stage Biotechnology - Immunology and Inflammatory Disorders. AskCyborg classifies Zura Bio Limited under Clinical-stage Biotechnology - Immunology and Inflammatory Disorders in its company registry.

Zura Bio is a clinical-stage biotechnology company that develops medicines for immune and inflammatory disorders in the United States. The company is dedicated to developing novel dual-pathway antibodies for a range o...

7/ 10Solid

Cyborg Score thesis

Clinical-stage immunology biotech with dual near-term catalysts and sufficient funding through key trial readouts in...

Read the full analyst-debate transcript →
Industry Clinical-stage Biotechnology - Immunology and Inflammatory Disorders
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Zura Bio Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Zura Bio Limited

AskCyborg analysts argue the bull and bear cases for Zura Bio Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Zura Bio Limited OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Zura Bio Limited Overview

Pro stress-test →

Zura Bio is a clinical-stage biotechnology company that develops medicines for immune and inflammatory disorders in the United States. The company is dedicated to developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases with unmet needs, with the goal of improving efficacy, safety, and dosing convenience for patients.

Strategic Profile

Pro stress-test →

The lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies: TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. TibuSHIELD is expanding enrollment to 225 participants with topline data expected in Q4 2026, while TibuSURE is enrolling with topline data expected in H1 2027.

Competitive Landscape

Pro stress-test →

Zura Bio operates in the autoimmune and inflammatory disease space, competing with larger established players developing IL-17 and BAFF pathway inhibitors. The dual-pathway bispecific approach differentiates the company's lead candidate from single-target monoclonal antibodies currently approved or in development for hidradenitis suppurativa and systemic sclerosis.

Industry Context

Zura Bio Limited operates in Clinical-stage Biotechnology - Immunology and Inflammatory Disorders.

Key facts

Founded: 2022 · Headquarters: Henderson, Nevada, United States · Employees: 30

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Zura Bio Limited.

  • Sandeep Kulkarni, M.D. was named CEO effective January 21, 2026; he co-founded and led Tourmaline Bio through its acquisition by Novartis.
  • Tibulizumab is an engineered bispecific dual-antagonist antibody that neutralizes interleukin (IL)-17A and B-cell activating factor.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026New CEO appointment: Sandeep Kulkarni replaces Robert Lisicki
  • 2026TibuSHIELD HS trial enrollment expanded to 225 participants; topline data expected Q4 2026
  • +1 moreTrack every material event for Zura Bio Limited as it happens. Explore monitoring →
Get alerted when Zura Bio Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

IxekizumabIL-17A antagonist approved for hidradenitis suppurativa→TNX-650 (BAFF inhibitor)BAFF pathway modulation for systemic sclerosis→BelimumabBAFF antagonist for lupus and systemic sclerosis→

Compare Zura Bio Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Zura Bio Limited operates in Clinical-stage Biotechnology - Immunology and Inflammatory Disorders. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-stage Biotechnology - Immunology and Inflammatory Disorders research →
NEW · MCP server

Ask your AI assistant about Zura Bio Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Zura Bio Limited and its top competitor on Cyborg Score”
“What did Zura Bio Limited do this quarter?”
“Is Zura Bio Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Zura Bio Limited do?+
Zura Bio is a clinical-stage biotechnology company that develops medicines for immune and inflammatory disorders in the United States. The company is dedicated to developing novel dual-pathway antibodies for a range o...
What is Zura Bio Limited's Cyborg Score?+
Zura Bio Limited has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Zura Bio Limited's main competitors?+
Named competitors include Ixekizumab, TNX-650 (BAFF inhibitor), Belimumab. The full competitive landscape is in the AskCyborg report.
How can I get the full Zura Bio Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Zura Bio Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Zura Bio Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.